Behavioral interventions have limited effectiveness, and patients treated for MA dependence have a high rate of relapse. 9 Although several medications have been tested, none has been proven to signi cantly reduce MA use in MA-dependent patients seeking treatment. [10] [11] [12] A promising approach that has not been thoroughly assessed is substitution therapy. Substitution therapies are well established in other addictions: methadone and buprenorphine reduce the use of heroin, 13 and nicotine replacement therapy doubles smoking cessation rates. 14 e exact mechanism of e cacy for substitution therapies is not yet understood, although several possibilities have been suggested. Such medications attenuate withdrawal symptoms, [15] [16] [17] potentially promoting engagement and retention in behavioral and psychosocial treatment; however, research ndings to date have been mixed. 18, 19 ese substitute medications are crosstolerant with the respective abused substances that they replace and similarly discriminated, but they typically have slower onsets of action and longer half-lives and are less reinforcing.
e relatively stable pharmacokinetic pro les of the replacement medications provide more constant drug levels as compared with the erratic concentrations characteristic of illicit drugs, possibly ARTICLES attenuating the subjective experiences of both intoxication and withdrawal.
No substitution therapy has been established for MA dependence. 20 Dextroamphetamine (d-AMP) is one of several agonist-like replacement therapies that have shown promise in preclinical studies as well as in laboratory studies in humans. 21 Oral d-AMP has been prescribed for thousands of MA users in England and Wales 22 and has been associated with decreases in intravenous (IV) MA use and criminal activity 19 and with increased treatment engagement. [23] [24] [25] Prior to the commencement of this study, there had been no placebo-controlled randomized trial of d-AMP for treatment of MA dependence.
e goal of our study was to determine the safety and ecacy of 60 mg sustained-release (SR) d-AMP in treating MA dependence. We selected the dosage of 60 mg per day on the basis of the available research to date. In a retrospective study of MA-dependent adults in treatment, an average of 43 mg of oral d-AMP was found to be as e ective in reducing IV use of MA as methadone had proved to be in reducing IV heroin use. 26 MA-experienced subjects who received a daily dose of 40 mg immediate-release d-AMP experienced improved treatment retention, reduced MA use, and less use of injection as a route of MA administration. 23 Previous studies also found that the use of d-AMP decreased problematic behaviors associated with drug use, 19 including IV administration of the drug, 26 thereby suggesting that d-AMP is an e ective intervention in those with more severe dependence, who tend to use the IV route.
RESULTS

Clinical characteristics
Of 230 subjects screened, 60 were randomized to either a placebo group (n = 30) or a d-AMP group (n = 30; see Figure 1 for study enrollment ow). e placebo and d-AMP groups did not di er signi cantly with respect to race, average age, or days of use of MA in the 30 days preceding screening. e majority of the subjects were Caucasian and male, with similar average ages (see Table 1 for participant demographics). At enrollment, subjects in the placebo group reported using MA a mean of 15.3 8.5 days out of the prior 30, and d-AMP group subjects reported 18.9 9.7 days of use. e quantity of MA used per day in the 30 days prior to enrollment by subjects in the placebo group was 319 353 mg; those in the d-AMP group used 307 283 mg.
Safety of d-AMP
No serious adverse events occurred during the trial. No adverse events were more likely to be reported by subjects in the d-AMP group than by subjects in the placebo group (Figure 2) . Dosing 
ARTICLES
condition also did not signi cantly a ect heart rate (F Figure 3 ). Of 16 possible instances of no new use, the placebo group had 2.9 4.9 instances, whereas the d-AMP group had 2.6 4.2. Medication adherence and attendance at psychosocial treatment sessions ere was no signi cant e ect of group on medication adherence or attendance at psychosocial treatment sessions. e percentage of dispensed medication taken did not signi cantly di er between the groups. Placebo subjects took 73.6% 15.2% and d-AMP subjects took 74.2% 12.2% of the dispensed medication (Mann-Whitney U-test: W = 457, P = 0.923). e number of psychosocial treatment sessions attended was also not a ected by group. Of a possible nine sessions, placebo group subjects ARTICLES attended 5.1 3.0, and d-AMP group subjects attended 5.6 3.0 sessions (Mann-Whitney U-test: W = 408, P = 0.535). At the rst visit a er day 1, all the subjects were asked which group they thought they were randomized to; 67% of the subjects in each group believed that they had been randomized to d-AMP.
DISCUSSION
e goal of our study was to determine the safety and e cacy of 60 mg SR d-AMP as substitution therapy for MA dependence. A variety of preclinical and clinical data indicate that this may be a useful approach for the treatment of MA dependence and could also serve to guide dose selection. Although we found that the overall e ect of d-AMP on MA use was not signi cant, the results show that 30 mg d-AMP taken twice daily is safe for MA users. e main nding of the study is that d-AMP reduces withdrawal symptoms and craving for MA. Although reductions in withdrawal and craving scores do not by themselves con rm the e cacy of d-AMP as a substitution therapy, the ndings in these domains do support the need for further exploration of d-AMP as a treatment for MA dependence. Both withdrawal symptoms and craving are postulated to increase relapse rates among MA users. [27] [28] [29] [30] erefore, these ndings suggest that one avenue for further consideration of d-AMP's e cacy is among more dependent, long-term MA users, who have been shown to experience more severe withdrawal symptoms. 31 We limited our dose to the maximum dose of SR d-AMP approved for use in the United States. A recent randomized placebo-controlled trial of d-AMP for MA dependence in Australia 32 used a design in which subjects could be titrated to a maximum dose of 110 mg/day. Signi cant improvements in treatment retention and reduction in MA dependence severity scores were reported. As compared with placebo, d-AMP signi cantly attenuated withdrawal symptoms, and a trend was noted for decrease in MA use. Severity of MA dependence was signi cantly reduced in the d-AMP group. e primary limitation of this study was the moderate size of the sample. Although it may be argued that an e ect that is detected in a study with only 30 subjects per group is not clinically signi cant, even a small e ect could be useful in guiding medication development e orts in a condition such as this, for which there is no e ective pharmacotherapy. In addition, given the time and expense required to conduct addiction treatment trials, developing more sensitive outcome measures of drug use should be a priority. 33 ere are several indicators of tolerance to d-AMP in our study sample. In a previous study, in which low doses of immediaterelease d-AMP (0.035-16 mg) were given to amphetamine-naive subjects, the drug produced stimulant-like e ects, including subjective ratings of "stimulated" and "like drug, " and increased diastolic and systolic blood pressure. 34, 35 In our study, d-AMP administration had no signi cant e ect on heart rate or blood pressure. Our subjects reported using >300 mg/day of MA, substantially more than the average daily amount of 50 mg reported in another study of MA-dependent adults. 36 Although we could not measure the purity of the MA used by our subjects, the absence of any e ect on heart rate and blood pressure a er the d-AMP dose, considered alongside self-reports of high doses of MA used, suggests that this population may have signi cant tolerance to amphetamines. e absence of any signi cant difference between the two groups with respect to adherence to the regimen implies that the oral d-AMP dispensed to the treatment group had not been diverted elsewhere; this also suggests tolerance to d-AMP. Our data are consistent with ndings to date suggesting that, if d-AMP is to be e ective for the treatment of MA dependence in highly amphetamine-tolerant individuals, it would have to be administered at higher doses. 37, 38 METHODS Study design. This was a placebo-controlled, double-blind, randomized clinical trial. Subjects received either 60 mg d-AMP SR or placebo daily for 8 weeks. This was given as a single dose on the first day and as two equally divided doses on subsequent days. Urn randomization was used to assign subjects to study groups so as to balance the groups with respect to baseline variables. 39 Factors controlled for were current attention deficit hyperactivity disorder, AWQ (score <18 vs. 19) , and days of MA use in the 30 days prior to randomization (<12 days vs. 13 days). For the latter two variables, median splits were determined on the basis of our previous work with MA. The trial was conducted at a single site, the Addiction & Pharmacology Research Laboratory in San Francisco, CA. The protocol was approved by the institutional review board of California Pacific Medical Center Research Institute and was registered at clinicaltrials.gov (identifier: NCT00630682).
Subjects. e study criteria required that subjects be between the ages of 18 and 50 years, meet Diagnostic and Statistical Manual of Mental Disorders IV-Text Revision criteria for MA dependence, be seeking treatment for MA dependence, and provide at least one MA-positive urine sample during screening. Exclusion criteria included serious medical illness, pregnancy, use of any investigational medication in the previous 30 days, a court mandate to participate in drug abuse treatment, and attendance in a drug or alcohol dependence treatment program within the 30 days prior to screening. Subjects were also excluded for the following diagnoses as determined by the Diagnostic Interview Schedule: current alcohol, opiate, or sedative-hypnotic dependence disorder requiring medical detoxi cation; presence of severe post-traumatic stress disorder, mania, or hypomania within the past 90 days; and lifetime history of schizophrenia, schizophreniform, or schizoa ective disorder.
Study medication. d-AMP is a US Food and Drug Administrationapproved stimulant indicated for the treatment of attention de cit hyperactivity disorder and narcolepsy. It is not detected as MA in urine or other specimens and is available commercially in sustained-release form. Peak blood levels are reached 8-10 h a er the dose is taken. 40 We used d-AMP SR capsules manufactured by Barr Laboratories, Pomona, NY. e Drug Prod Services Laboratory at University of California, San Francisco, prepared both the active and the placebo capsules. d-AMP capsules for the study were made by repackaging 15-mg SR capsules purchased from Barr Laboratories into 30-mg capsules. e latter were identical in appearance to the placebo capsules, which were lled with lactose.
Psychosocial treatment. Subjects received 50-min, manual-based, individual motivational enhancement therapy sessions once a week for 9 weeks.
is intensive therapy 41 is a modi cation of Miller's three-session treatment for alcohol-dependent subjects. 42 MA urinalysis. Urine samples were collected two times a week and assayed for MA qualitatively on site with immunoassay devices (Redwood Biotech, Santa Rosa, CA); the cuto value was 1,000 ng/ml. Urine samples ARTICLES that tested positive were then sent to Quest Diagnostics (Nichols Institute, San Juan Capistrano, CA) for quanti cation of MA levels using gas chromatography/mass spectrometry. e subjects were asked at each visit to report the days of MA use since the previous study visit.
Although the presence of MA in urine indicates use at some time, it may be due to carryover from the preceding sample. Using known pharmacokinetic properties of benzoylecgonine, Preston et al. 43 For each of the three measures of use (urinalysis, self-report, and newuse criteria), we analyzed a number of statistics: number of abstinence events, time to rst use, longest consecutive period of abstinence, and probability of use. For brevity, we report only the number of abstinence events.
Secondary outcome assessments. e subjects made two visits a week to the center for 8 weeks a er randomization. At each visit, we collected samples for urinalysis and data on self-reported MA use. For the selfreport data, a timeline follow-back instrument 45 was used to record the number of days in which any MA use occurred and the quantity of MA used each day. Subjective assessments included a 100 mm visual analog craving scale and the AWQ. 46 e Desires for Speed Questionnaire is a brief, modi ed version of the Desires for Alcohol Questionnaire. e AWQ is a brief, reliable, and valid 10-item questionnaire for the evaluation of acute signs and symptoms of MA withdrawal in newly abstinent MA users, 47 including hypersomnia, MA craving, dysphoria, lack of energy, and increase in appetite. Items also tap three aspects of amphetamine withdrawal, namely, hyperarousal, reversed vegetative, and anxiety. 48 A checklist similar to the ones used in other trials of US Food and Drug Administration-approved medications 21, 49 was used to assess the prevalence of 34 potential adverse events, selected a priori on the basis of likelihood of occurrence and severity. Once every week, the subjects returned their medication bottles and were given new ones. Unused capsules were counted and then disposed of. A medication accountability form was also used at the weekly visit to document the dates on which medications were dispensed and returned. is form also documented the subject's self-report about the medication dispensed, i.e., how much of the medication was ingested, stolen, lost, or returned.
Statistics. For overall study measures (e.g., total number of MA-negative urine samples, total number of therapy sessions attended), we used Mann-Whitney U-tests to determine whether there was any di erence in the numbers of these events by group (medication and placebo). To determine whether dosing condition a ected time-dependent measures, we made linear mixed-e ects models in which baseline-corrected scores were predicted by group and time. For outcomes in which both group and time were signi cant predictors, we compared the conditions at individual time points using post hoc z-tests. For models in which only the dosing condition had a signi cant e ect, we constructed new models predicting peak changes by group and used post hoc z-tests to compare the individual dosing conditions.
